Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

All patients in both treatment arms completed the 20-week double-blind period of the study. In the 20-week double-blind period of the study, similar proportion of patients had adverse events (AEs) in ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...

Detailed price information for Fennec Pharmaceuticals Inc (FRX-T) from The Globe and Mail including charting and trades.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.